BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Has $42.35 Million Position in Agilent Technologies, Inc. $A

Key Points

• British Columbia Investment Management Corp increased its stake in Agilent Technologies by 9.5%, owning 362,019 shares valued at approximately $42.3 million as of the latest 13F filing.
• Agilent Technologies reported $1.31 earnings per share (EPS) for the most recent quarter, exceeding analysts' expectations and showcasing a 6% increase in revenue year-over-year.
• A majority of Agilent Technologies' stock, approximately 87.41%, is held by hedge funds and institutional investors, indicating significant confidence in the company's performance.

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its holdings in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 9.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 362,019 shares of the medical research company's stock after buying an additional 31,299 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp owned 0.13% of Agilent Technologies worth $42,349,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. GAMMA Investing LLC raised its holdings in Agilent Technologies by 15,648.1% during the first quarter. GAMMA Investing LLC now owns 627,247 shares of the medical research company's stock worth $73,375,000 after purchasing an additional 623,264 shares in the last quarter. Two Sigma Investments LP lifted its holdings in shares of Agilent Technologies by 345.9% in the fourth quarter. Two Sigma Investments LP now owns 769,897 shares of the medical research company's stock valued at $103,428,000 after buying an additional 597,249 shares during the period. Iron Triangle Partners LP acquired a new stake in shares of Agilent Technologies in the fourth quarter valued at $80,110,000. Mackenzie Financial Corp boosted its stake in Agilent Technologies by 141.5% during the first quarter. Mackenzie Financial Corp now owns 935,893 shares of the medical research company's stock valued at $109,481,000 after buying an additional 548,344 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in Agilent Technologies by 12.3% during the fourth quarter. Northern Trust Corp now owns 4,192,790 shares of the medical research company's stock worth $563,259,000 after acquiring an additional 457,713 shares during the period.

Insider Activity at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the firm's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total value of $177,099.52. Following the completion of the transaction, the chief executive officer owned 37,448 shares in the company, valued at $4,397,893.12. This trade represents a 3.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Analyst Ratings Changes

A number of brokerages have weighed in on A. Wall Street Zen raised shares of Agilent Technologies from a "hold" rating to a "buy" rating in a report on Saturday, June 28th. Leerink Partners lifted their price target on shares of Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research report on Friday, May 30th. Barclays increased their price objective on Agilent Technologies from $115.00 to $125.00 and gave the company an "equal weight" rating in a research report on Tuesday, June 24th. TD Cowen raised their price objective on Agilent Technologies to $150.00 and gave the stock a "buy" rating in a research note on Thursday, May 29th. Finally, JPMorgan Chase & Co. reduced their target price on Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating for the company in a report on Thursday, May 29th. Six investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Agilent Technologies presently has a consensus rating of "Moderate Buy" and an average price target of $138.83.

Agilent Technologies Stock Up 0.4%

Shares of A traded up $0.53 on Wednesday, hitting $118.83. The company's stock had a trading volume of 1,680,157 shares, compared to its average volume of 1,941,331. The company has a quick ratio of 1.60, a current ratio of 2.09 and a debt-to-equity ratio of 0.55. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $153.84. The firm's fifty day moving average price is $117.93 and its 200-day moving average price is $116.88. The firm has a market capitalization of $33.76 billion, a price-to-earnings ratio of 29.34, a P/E/G ratio of 3.62 and a beta of 1.22.

Agilent Technologies (NYSE:A - Get Free Report) last released its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.37. Agilent Technologies had a return on equity of 25.92% and a net margin of 17.59%. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, equities research analysts expect that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.